Eisai & Genomics Plc Collaborate
News Apr 13, 2015
Eisai Co., Ltd. and Genomics plc have entered into a collaborative agreement to use Genomics' sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai's drug discovery process, including target selection, target validation, indication selection and repositioning.
Both companies believe that human genetics and genomics can add great value to the drug development process. Genomics, the Oxford based genome analytics company, will be partnering with Eisai's new Integrated Human Genomics (IHGx) Research Unit which operates directly under the supervision of Eisai Product Creation Systems' Chief Clinical Officer.
“Eisai is delighted to be working with Genomics,” states Dr. Nadeem Sarwar, Director of the IHGx Research Unit, “Genomics' founders are internationally recognized leaders in the analysis and interpretation of human genetic data. This collaboration is another indication of Eisai's commitment to leveraging genomic knowledge to accelerate the discovery and development of impactful new medicines.”
Professor Peter Donnelly, a director and founder of Genomics, says, “Genomics' research work with Eisai will demonstrate the real value that powerful analyses of large genomic databases can add to drug development pipelines.”
“Genomics is excited to be working with one of the world's leading research and development-based pharmaceutical companies in the rapidly growing area of genomic analysis. This exciting new area promises to potentially make a positive difference to medicine,” adds John Colenutt, CEO of Genomics.
Nano and Micro Join Forces to Treat OsteoarthritisNews
There is currently no treatment for curing osteoarthritis, which affects 80% of the population over 75 years of age. But researchers who have been studying the problem have come up with a new treatment that delivers previously-identified active principles directly into the joint in the form of nanocrystals inserted into microparticles.READ MORE